HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Andreas von Deimling Selected Research

Ependymoma

1/2017The current consensus on the clinical management of intracranial ependymoma and its distinct molecular variants.
11/2012Nestin expression identifies ependymoma patients with poor outcome.
11/2011A novel human high-risk ependymoma stem cell model reveals the differentiation-inducing potential of the histone deacetylase inhibitor Vorinostat.
7/2010Molecular staging of intracranial ependymoma in children and adults.
3/2009Stepwise accumulation of distinct genomic aberrations in a patient with progressively metastasizing ependymoma.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Andreas von Deimling Research Topics

Disease

226Neoplasms (Cancer)
12/2022 - 07/2002
103Glioma (Gliomas)
12/2022 - 10/2004
90Glioblastoma (Glioblastoma Multiforme)
05/2022 - 08/2002
39Astrocytoma (Pilocytic Astrocytoma)
12/2022 - 08/2002
27Brain Neoplasms (Brain Tumor)
01/2022 - 05/2006
20Meningioma (Meningiomas)
12/2022 - 09/2006
17Oligodendroglioma
12/2022 - 10/2004
17Medulloblastoma
01/2022 - 03/2010
16Melanoma (Melanoma, Malignant)
01/2022 - 02/2012
11Neoplasm Metastasis (Metastasis)
11/2021 - 08/2004
11Sarcoma (Soft Tissue Sarcoma)
01/2021 - 06/2011
11Neurofibrosarcoma (MPNST)
01/2016 - 02/2004
9Carcinogenesis
01/2020 - 04/2004
8Disease Progression
11/2021 - 10/2005
7Neuroblastoma
03/2020 - 05/2007
6Carcinoma (Carcinomatosis)
11/2021 - 03/2005
5Necrosis
01/2020 - 04/2009
5Ependymoma
01/2017 - 03/2009
4Solitary Fibrous Tumors
01/2022 - 05/2013
4Primitive Neuroectodermal Tumors (PNET)
01/2021 - 01/2016
4Neurilemmoma (Schwannoma)
01/2020 - 04/2014
4Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
09/2017 - 08/2010
4Lung Neoplasms (Lung Cancer)
12/2014 - 02/2009
3Chromosome Aberrations (Chromosome Abnormalities)
01/2022 - 03/2009
3Lymphoma (Lymphomas)
01/2021 - 08/2004
3Hemangiosarcoma (Angiosarcoma)
01/2021 - 04/2014
3Genomic Instability
12/2019 - 01/2016
3Chondrosarcoma
08/2018 - 04/2014
3Inflammation (Inflammations)
04/2016 - 06/2007
3Colorectal Neoplasms (Colorectal Cancer)
12/2014 - 02/2012
3Breast Neoplasms (Breast Cancer)
12/2014 - 11/2003
3Adenocarcinoma
11/2014 - 10/2013
3Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
11/2014 - 06/2011

Drug/Important Bio-Agent (IBA)

72Proteins (Proteins, Gene)FDA Link
12/2022 - 08/2002
55Isocitrate Dehydrogenase (Isocitrate Dehydrogenase (NAD+))IBA
05/2022 - 12/2008
44DNA (Deoxyribonucleic Acid)IBA
12/2022 - 08/2002
34Biomarkers (Surrogate Marker)IBA
12/2022 - 12/2007
30Biological ProductsIBA
01/2022 - 08/2004
23Temozolomide (Temodar)FDA LinkGeneric
01/2022 - 10/2005
20ParaffinIBA
12/2022 - 09/2009
19RNA (Ribonucleic Acid)IBA
10/2022 - 02/2004
17Messenger RNA (mRNA)IBA
01/2020 - 03/2005
14Formaldehyde (Formol)FDA Link
12/2022 - 11/2009
14Pharmaceutical PreparationsIBA
12/2021 - 05/2007
13EnzymesIBA
01/2021 - 09/2006
10Histones (Histone)IBA
01/2019 - 01/2010
9AntigensIBA
05/2022 - 02/2015
9alpha-hydroxyglutarateIBA
10/2020 - 01/2012
8MethyltransferasesIBA
01/2021 - 01/2011
8Codon (Codons)IBA
01/2021 - 12/2008
8LigandsIBA
01/2013 - 11/2003
7Peptides (Polypeptides)IBA
01/2022 - 02/2006
7ErbB Receptors (EGF Receptor)IBA
01/2021 - 12/2008
7Tryptophan (L-Tryptophan)FDA Link
01/2021 - 10/2011
7MicroRNAs (MicroRNA)IBA
01/2020 - 04/2009
6Telomerase (Telomerase Reverse Transcriptase)IBA
01/2021 - 12/2013
6Phosphotransferases (Kinase)IBA
01/2020 - 01/2012
6Small Interfering RNA (siRNA)IBA
04/2019 - 01/2008
6Alkylating AgentsIBA
02/2016 - 01/2012
6Monoclonal AntibodiesIBA
10/2015 - 01/2010
6O(6)-Methylguanine-DNA MethyltransferaseIBA
07/2014 - 12/2009
5NucleotidesIBA
11/2021 - 01/2016
5Amino AcidsFDA Link
01/2021 - 08/2002
5VaccinesIBA
01/2021 - 08/2014
5Aryl Hydrocarbon Receptors (Aryl Hydrocarbon Receptor)IBA
01/2021 - 10/2011
5Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA
11/2020 - 12/2008
5Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
01/2018 - 11/2008
5Neurofibromin 1 (Neurofibromin)IBA
01/2016 - 07/2004
4Neoplasm Antigens (Tumor Antigens)IBA
05/2022 - 11/2018
4ProteomeIBA
01/2022 - 11/2018
4ChromatinIBA
12/2019 - 01/2012
4TensinsIBA
01/2018 - 09/2005
4Mitogen-Activated Protein KinasesIBA
01/2018 - 03/2013
4EpitopesIBA
01/2018 - 02/2015
4Matrix Metalloproteinases (MMPs)IBA
01/2018 - 09/2006
4Platelet-Derived Growth Factor Receptors (Platelet-Derived Growth Factor Receptor)IBA
01/2018 - 02/2004
4isocitric acid (isocitrate)IBA
09/2017 - 08/2010
4Transcription Factors (Transcription Factor)IBA
01/2015 - 09/2006
4Histone Deacetylase InhibitorsIBA
05/2014 - 01/2009
4Mutant Proteins (Protein, Mutant)IBA
03/2013 - 02/2012
3KynurenineIBA
01/2021 - 10/2011
3Cyclin-Dependent Kinases (cdk Proteins)IBA
12/2020 - 12/2009
3Bevacizumab (Avastin)FDA Link
10/2020 - 10/2015
3SurvivinIBA
03/2020 - 11/2008
3Interleukin-6 (Interleukin 6)IBA
01/2019 - 08/2010
3Membrane Proteins (Integral Membrane Proteins)IBA
01/2019 - 09/2009
3Fas Ligand Protein (Fas Ligand)IBA
01/2018 - 03/2008
3Phosphoric Monoester Hydrolases (Phosphatases)IBA
01/2018 - 09/2005
3Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
01/2018 - 07/2010
3Lomustine (CCNU)FDA Link
11/2017 - 12/2009
3Tretinoin (Retinoic Acid)FDA LinkGeneric
10/2015 - 11/2003
3Tyrosine Kinase InhibitorsIBA
11/2014 - 03/2006
3AntibodiesIBA
08/2014 - 02/2004

Therapy/Procedure

80Therapeutics
01/2022 - 07/2002
36Radiotherapy
01/2022 - 01/2007
34Drug Therapy (Chemotherapy)
01/2022 - 01/2005
9Immunotherapy
05/2022 - 02/2015
8Chemoradiotherapy
11/2016 - 03/2009
5Aftercare (After-Treatment)
01/2021 - 05/2006
5Ligation
02/2015 - 07/2010